Based on data from the present study and others, BRAF-mutant GIST does not respond well to KIT TKIs but does respond well to combination BRAF and MEK inhibition, as is seen in other BRAF-driven cancers, such as melanoma. The gene discussed is MAP2K7; the disease is melanoma.